From stem cells to pancreatic β-cells: strategies, applications, and potential treatments for diabetes
- PMID: 38642274
- DOI: 10.1007/s11010-024-04999-x
From stem cells to pancreatic β-cells: strategies, applications, and potential treatments for diabetes
Abstract
Loss and functional failure of pancreatic β-cells results in disruption of glucose homeostasis and progression of diabetes. Although whole pancreas or pancreatic islet transplantation serves as a promising approach for β-cell replenishment and diabetes therapy, the severe scarcity of donor islets makes it unattainable for most diabetic patients. Stem cells, particularly induced pluripotent stem cells (iPSCs), are promising for the treatment of diabetes owing to their self-renewal capacity and ability to differentiate into functional β-cells. In this review, we first introduce the development of functional β-cells and their heterogeneity and then turn to highlight recent advances in the generation of β-cells from stem cells and their potential applications in disease modeling, drug discovery and clinical therapy. Finally, we have discussed the current challenges in developing stem cell-based therapeutic strategies for improving the treatment of diabetes. Although some significant technical hurdles remain, stem cells offer great hope for patients with diabetes and will certainly transform future clinical practice.
Keywords: Cell reprogramming; Cell therapy; Diabetes; Disease modeling; Drug discovery; Pancreatic β-cells; Stem cell; β-cell heterogeneity.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no conflict interest. Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors.
Similar articles
-
Advances in the Generation of Functional β-cells from Induced Pluripotent Stem Cells As a Cure for Diabetes Mellitus.Curr Drug Targets. 2018;19(13):1463-1477. doi: 10.2174/1389450119666180605112917. Curr Drug Targets. 2018. PMID: 29874998 Review.
-
Differentiation of human pluripotent stem cells into β-cells: Potential and challenges.Best Pract Res Clin Endocrinol Metab. 2015 Dec;29(6):833-47. doi: 10.1016/j.beem.2015.10.011. Epub 2015 Oct 30. Best Pract Res Clin Endocrinol Metab. 2015. PMID: 26696513 Review.
-
Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells.Int J Mol Sci. 2016 Feb 19;17(2):256. doi: 10.3390/ijms17020256. Int J Mol Sci. 2016. PMID: 26907255 Free PMC article. Review.
-
Generation of insulin-producing cells from pluripotent stem cells: from the selection of cell sources to the optimization of protocols.Rev Diabet Stud. 2010 Summer;7(2):82-92. doi: 10.1900/RDS.2010.7.82. Epub 2010 Aug 10. Rev Diabet Stud. 2010. PMID: 21060967 Free PMC article. Review.
-
Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model.Stem Cells Dev. 2012 Sep 20;21(14):2642-55. doi: 10.1089/scd.2011.0665. Epub 2012 Jun 1. Stem Cells Dev. 2012. PMID: 22512788 Free PMC article.
Cited by
-
Repair, Regeneration, and Replacement, Revisited (Redux).J Diabetes Sci Technol. 2025 May;19(3):605-610. doi: 10.1177/19322968251326906. Epub 2025 Mar 15. J Diabetes Sci Technol. 2025. PMID: 40088132 Free PMC article. No abstract available.
-
Differentiation of patient-specific induced pluripotent stem cells derived from type 1 diabetes peripheral blood mononuclear cells into pancreatic β-like cells.World J Stem Cells. 2025 Jul 26;17(7):104607. doi: 10.4252/wjsc.v17.i7.104607. World J Stem Cells. 2025. PMID: 40740538 Free PMC article.
-
A stepwise approach to deriving functional β-cells from human embryonic or induced pluripotent stem cells.Med Rev (2021). 2024 Oct 16;5(1):23-34. doi: 10.1515/mr-2024-0039. eCollection 2025 Feb. Med Rev (2021). 2024. PMID: 39974557 Free PMC article. Review.
References
-
- Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WHH, Zhang P, Bommer C, Kuo SH, Boyko EJJ, Magliano DJ (2022) IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Practice. https://doi.org/10.1016/j.diabres.2021.109119 - DOI
-
- ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, Assoc AD (2023) Classification and diagnosis of diabetes. Diabetes Care 46:S19–S40. https://doi.org/10.2337/dc23-S002 - DOI - PubMed
-
- He SY, Yu XQ, Cui DX, Liu Y, Yang SS, Zhang HM, Hu WX, Su ZG (2023) Nuclear factor-Y mediates pancreatic beta-cell compensation by repressing reactive oxygen species-induced apoptosis under metabolic stress. Chin Med J 136:922–932. https://doi.org/10.1097/Cm9.0000000000002645 - DOI - PubMed - PMC
-
- Dal Canto E, Ceriello A, Ryden L, Ferrini M, Hansen TB, Schnell O, Standl E, Beulens JWJ (2019) Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 26:25–32. https://doi.org/10.1177/2047487319878371 - DOI
-
- Zhang XP, Deng D, Cui DX, Liu Y, He SY, Zhang HM, Xie YR, Yu XQ, Yang SS, Chen YL, Su ZG (2022) Cholesterol sulfate exerts protective effect on pancreatic beta-cells by regulating beta-cell mass and insulin secretion. Front Pharmacol. https://doi.org/10.3389/fphar.2022.840406 - DOI - PubMed - PMC
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical